<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02038569</url>
  </required_header>
  <id_info>
    <org_study_id>LP0076-1017</org_study_id>
    <nct_id>NCT02038569</nct_id>
  </id_info>
  <brief_title>Effect of Calcipotriol Plus Betamethasone Dipropionate Gel on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to 16 Years, 11 Months) With Scalp and Body Psoriasis</brief_title>
  <official_title>Effect of Calcipotriol Plus Betamethasone Dipropionate Gel on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to 16 Years, 11 Months) With Scalp and Body Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An international, multi-centre, prospective, non-controlled, open, single-group, 8-week trial
      in adolescent subjects (aged 12 to 16 years, 11 months) with scalp and body psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">February 13, 2018</completion_date>
  <primary_completion_date type="Actual">February 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Drug Reactions (ADRs)</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Or at end of study as defined in protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjects with serum cortisol concentration of ≤18 mcg/dl at 30 minutes after ACTH-challenge</measure>
    <time_frame>Week 4</time_frame>
    <description>Or at end of study as defined in protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjects with serum cortisol concentration of ≤18 mcg/dl at 30 minutes after ACTH-challenge</measure>
    <time_frame>Week 8</time_frame>
    <description>Or at end of study as defined in protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in albumin-corrected serum calcium from baseline (SV2)</measure>
    <time_frame>Week 4</time_frame>
    <description>Or at end of study as defined in protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in albumin-corrected serum calcium from baseline (SV2)</measure>
    <time_frame>Week 8</time_frame>
    <description>Or at end of study as defined in protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in 24-hour urinary calcium excretion from baseline (SV2)</measure>
    <time_frame>Week 4</time_frame>
    <description>Or at end of study as defined in protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in 24-hour urinary calcium excretion from baseline (SV2)</measure>
    <time_frame>Week 8</time_frame>
    <description>Or at end of study as defined in protocol</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>LEO 80185</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 80185</intervention_name>
    <arm_group_label>LEO 80185</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (all subjects):

          -  Clinical signs of psoriasis vulgaris on both the scalp and body (trunk and/or limbs)

          -  At SV2 and Visit 1, a clinical diagnosis of scalp and body (trunk and/or limbs)
             psoriasis which is:

               -  of an extent of 10 to 35% of the body surface area (excluding psoriatic lesions
                  of the face and sensitive areas. Sensitive areas include armpits, groin, under
                  the breasts and in other skin folds around the genitals and buttocks), and

               -  of at least moderate severity according to the investigator's global assessment
                  of disease severity on the body.

          -  A serum albumin-corrected calcium level below the upper reference limit at SV2

        Inclusion Criteria (for subjects performing HPA axis assessments):

          -  At SV2 and Visit 1, a clinical diagnosis of scalp psoriasis which is:

               -  more than or equal to 20% of the scalp area, and

               -  of at least moderate severity according to the investigator's global assessment
                  of disease severity on the scalp.

          -  Subjects with a normal HPA axis function at SV2 including serum cortisol concentration
             above 5 mcg/dl before ACTH challenge and serum cortisol concentration above 18 mcg/dl
             30 minutes after ACTH challenge.

        Inclusion Criteria (for subjects not performing HPA axis assessments):

          -  At SV2 and Visit 1, a clinical diagnosis of scalp psoriasis which is:

               -  more than or equal to 10% of the scalp area, and

               -  of at least moderate severity according to the investigator's global assessment
                  of disease severity on the scalp.

        Exclusion Criteria (all subjects):

          -  Systemic treatment with biological therapies (marketed or not marketed), with a
             possible effect on scalp and/or body psoriasis within the following time period prior
             to Visit 1 and during the trial:

               -  etanercept - within 4 weeks prior to Visit 1

               -  adalimumab, infliximab - within 2 months prior to Visit 1

               -  ustekinumab - within 4 months prior to Visit 1

               -  experimental products - within 4 weeks/5 half-lives (whichever is longer) prior
                  to Visit 1

          -  Systemic treatment with therapies other than biologicals, with a possible effect on
             scalp and/or body psoriasis (e.g., retinoids, immunosuppressants, PUVA) within 4 weeks
             prior to Visit 1 (Day 0) or during the trial.

          -  UVB therapy within 2 weeks prior to Visit 1 or during the trial.

          -  Any topical treatment on the scalp and body (except for emollients and non-steroid
             medicated shampoos) within 2 weeks prior to Visit 1 or during the trial.

          -  Systemic calcium, vitamin D supplements, antacids, diuretics, antiepileptics,
             diphosphonates or calcitonin within 4 weeks prior to SV2 or during the trial.

          -  Planned initiation of, or changes to, concomitant medication that could affect
             psoriasis (e.g., betablockers, chloroquine, lithium, ACE inhibitors) during the trial.

          -  Current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis.

          -  Subjects with any of the following conditions present on the treatment areas on scalp
             and/or body: viral (e.g., herpes or varicella) lesions of the skin, fungal and
             bacterial skin infections, parasitic infections, skin manifestations in relation to
             syphilis or tuberculosis, rosacea, acne vulgaris, acne rosacea, atrophic skin, striae
             atrophicae, fragility of skin veins, ichthyosis, ulcers and wounds.

          -  Other inflammatory skin diseases that may confound the evaluation of scalp and/or body
             psoriasis.

          -  Planned excessive exposure to sun during the trial that may affect scalp and/or body
             psoriasis.

          -  Known or suspected severe renal insufficiency or severe hepatic disorders.

          -  Known or suspected disorders of calcium metabolism associated with hypercalcaemia.

          -  Any clinically significant abnormality following review of screening laboratory tests
             (blood and urine samples), physical examination or blood pressure/heart rate
             measurement performed at SV2.

          -  Current participation in any other interventional clinical trial.

          -  Previously enrolled in this trial.

          -  Subjects who have received treatment with any non-marketed drug substance (i.e., an
             agent which has not yet been made available for clinical use following registration)
             within a month prior to SV1 or longer, if the class of substance required a longer
             wash-out as defined above (e.g., biological treatments).

          -  Subjects or parent(s) or legal guardian known or suspected of being unlikely to comply
             with the Clinical Trial Protocol (e.g., alcoholism, drug dependency or psychotic
             state).

          -  Females who are pregnant, or of child-bearing potential and wishing to become pregnant
             during the trial, or who are breast-feeding.

          -  Females of child-bearing potential with positive pregnancy test at SV2.

          -  Subject (or their partner) not using an adequate method of contraception according to
             national requirements.

        Exclusion Criteria (for subjects performing HPA axis assessments)

          -  A history of serious allergy, allergic asthma or serious allergic skin rash.

          -  Known or suspected hypersensitivity to any component of CORTROSYN® (including
             ACTH/cosyntropin/tetracosactide)

          -  Systemic treatment with corticosteroids (including inhaled and nasal steroids) within
             12 weeks prior to SV2 or during the trial.

          -  Topical treatment with corticosteroids within 2 weeks prior to SV2 or during the
             trial.

          -  Oestrogen therapy (including contraceptives) or any other medication known to affect
             cortisol levels levels or HPA axis integrity within 4 weeks prior to SV2 or during the
             trial.

          -  Enzymatic inductors (e.g., barbiturates, phenytoin, rifampicin) within 4 weeks prior
             to SV2 or during the trial.

          -  Systemic or topical cytochrome P450 inhibitors (e.g., ketoconazole, itraconazole,
             metronidazole) within 4 weeks prior to SV2 or during the trial. Topical ketoconazole 2
             weeks prior to SV2.

          -  Hypoglycemic sulfonamides within 4 weeks prior to SV2 or during the trial.

          -  Antidepressive medications within 4 weeks prior to SV2 or during the trial.

          -  Known or suspected endocrine disorder that may affect the results of the ACTH
             challenge test.

          -  Clinical signs or symptoms of Cushing's disease or Addison's disease.

          -  Subjects with diabetes mellitus.

          -  Known or suspected cardiac condition.

          -  Not following nocturnal sleep patterns.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence Eichenfield, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rady Chilidren's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rady's Children Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center, Morsani Center for Advanced Healthcare</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Specialists, PC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Roosevelt Hospital</name>
      <address>
        <city>Forest Hills</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Partners</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <zip>12095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology and Laser Center of Charleston, PA</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winnipeg Clinic</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3C 0N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adult, Pediatric and Laser Derma</name>
      <address>
        <city>St-John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1A 4Y3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynderm Research Inc.</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Centre for Dermatology</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <state>Alpe-Maritimes</state>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Medical</name>
      <address>
        <city>Martigues</city>
        <state>Bouches-du-Rhône</state>
        <zip>13500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHI de Cornouaille</name>
      <address>
        <city>Quimper</city>
        <state>Finistère</state>
        <zip>29107</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katholisches Kinderkrankenhaus</name>
      <address>
        <city>Hamburg</city>
        <zip>22149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endo - Med. Centrum Medyczne Clinic</name>
      <address>
        <city>Karczew</city>
        <zip>05-480</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Med.-Laser Clinic</name>
      <address>
        <city>Lublin</city>
        <zip>20-146</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczny Ofrodek Leczniczo Clinic</name>
      <address>
        <city>Ostróda</city>
        <zip>14-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medycyna Kliniczna Clinic</name>
      <address>
        <city>Warszawa</city>
        <zip>00-660</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derm Medica Sp.zo.o. Clinic</name>
      <address>
        <city>Wrocław</city>
        <zip>51-318</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinica de Diagnostic Rapid S.A. Clinic</name>
      <address>
        <city>Brasov</city>
        <zip>500152</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic &quot;Colentina&quot;</name>
      <address>
        <city>Bucharest</city>
        <zip>20125</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta Cluj-Napoca</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400006</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Medical Individual Tatu G. Alin Laurentiu</name>
      <address>
        <city>Galati</city>
        <zip>800101</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iasiprest SRL Dermato-Venerology</name>
      <address>
        <city>Iasi</city>
        <zip>700381</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean Mures</name>
      <address>
        <city>Targu-Mures</city>
        <zip>800373</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Municipal de Urgenta Timisoara</name>
      <address>
        <city>Timisoara</city>
        <zip>300077</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monklands Hospital</name>
      <address>
        <city>Airdrie</city>
        <state>Lanarkshire</state>
        <zip>ML6 OJ5</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Whipps Cross University Hospital</name>
      <address>
        <city>Leytonstone</city>
        <state>London</state>
        <zip>E11 1NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Woolos Hospital</name>
      <address>
        <city>Stow Hill, Newport</city>
        <state>Monmouthshire</state>
        <zip>NP20 4SZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2014</study_first_submitted>
  <study_first_submitted_qc>January 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2014</study_first_posted>
  <last_update_submitted>March 2, 2018</last_update_submitted>
  <last_update_submitted_qc>March 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
    <mesh_term>Calcipotriene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

